BioSpace

OCTOBER 31, 2022

Verge Genomics dosed its first patient in a Phase I trial studying VRG50635, while Stealth Bio's SBT-272 was granted Orphan Drug designation by the FDA.

Genome 93

Genome Genomics Trials Drugs 93

pharmaphorum

OCTOBER 31, 2022

Verge Genomics has joined a select group of biotechs who have taken a drug discovered and developed using artificial intelligence into human testing. The post Verge Genomics takes AI-sourced drug for ALS into clinic appeared first on.

Genome 134

Genome Genomics Drugs RNA 134

Drug Discovery World

JANUARY 11, 2024

Verge Genomics has initiated a Phase Ib proof-of-concept study for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS) with VRG50635. ” The post AI-discovered ALS drug trial uses unique remote monitoring appeared first on Drug Discovery World (DDW).

Drug Trials 98

Drug Trials Trials Drugs Genome 98

BioSpace

OCTOBER 24, 2021

C2i Genomics plans to make sophisticated AI-informed cancer diagnostics and tumor monitoring available throughout the world, regardless of where patients or clinical trials are located.

Genome 99

Genome Genomics Clinical Trials Clinical Trials 99

BioSpace

JULY 19, 2022

CAMP4 Therapeutics raised another $100 million in financing to advance its approach into the “dark side of the genome” and drive two therapeutics into clinical trials next year.

Genome 93

Genome Genomics Clinical Trials Clinical Trials 93

Drug Discovery World

JUNE 21, 2023

The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE), Exact Sciences, Guardant Health, Illumina, MSD and Novartis have come together to launch the European Coalition for Access to Comprehensive Genomic Profiling (ECGP).

Genome 52

Genome Genomics Medicine Clinical Trials 52

Drug Discovery World

NOVEMBER 7, 2022

A new study led by Medical Research Council-funded researchers from UCL has found that tailoring the analysis of whole genome sequencing to individual patients could double the diagnostic rates of rare diseases. . Consequently, the UK has established itself at the forefront of diagnostic whole genome sequencing. Context .

Genome 52

Genome Genomics Genetics Genetic Disease 52

Rethinking Clinical Trials

AUGUST 17, 2023

When research and clinical care are deliberately integrated in an embedded pragmatic clinical trial, the nature and extent of investigators’ obligations to patient-subjects are blurred, as is the clinician’s duty to participate is such research. Wilfond, Sinem Toraman Turk, Stephanie A. Kraft, Elliott M. Weiss, Philip I.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130

pharmaphorum

MARCH 12, 2021

The UK regulator has authorised Eli Lilly’s targeted cancer drug Retsevmo for tumours with RET fusion positive lung cancers and thyroid cancers, which the company said could herald a new era of genomic medicine for the NHS. The post New era of genomic medicine begins as UK approves Lilly’s Retsevmo appeared first on.

Genome 111

Genome Genomics Medicine Regulation 111

Roots Analysis

FEBRUARY 27, 2024

The global genome editing market is anticipated to grow at a CAGR of 12.6% The global genome editing market is anticipated to grow at a CAGR of 12.6% Recently, in July 2019, a first in vivo clinical trial for a CRISPR-based therapy was initiated. during the forecast period 2023-2035. during the forecast period 2023-2035.

Genome 40

Genome Genomics Gene Gene Editing 40

BioPharma Reporter

FEBRUARY 4, 2021

Illumina, a DNA sequencing and array-based technology specialist, is supporting the Belgian Society of Medical Oncology (BSMO) in a pilot study examining the use of comprehensive genomic profiling (CGP) in 864 patients with advanced metastatic cancer.

Genome 98

Genome Genomics DNA Trials 98

Pharmaceutical Technology

APRIL 12, 2023

Repotrectinib, a tyrosine kinase inhibitor (TKI), is in an ongoing registrational Phase I/II trial (NCT03093116) for patients ROS1+ advanced non-small cell lung cancer (NSCLC) and NTRK+ advanced solid tumors, that are either TKI-naïve or TKI-pretreated. The ROS1 gene is altered in approximately in 1-2% of lung cancer patients.

Genome 130

Genome Genomics In-Vitro Gene 130

BioTech 365

FEBRUARY 2, 2022

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: FDA puts LogicBio genome editing therapy trial on hold after 2nd infant suffers adverse event.FDA puts LogicBio genome editing therapy trial on hold after 2nd infant suffers … Continue reading →

Genome 40

Genome Genomics Trials Research 40

Outsourcing Pharma

FEBRUARY 18, 2021

The two companies will work to advance precision cancer medicine by harnessing genomics data in trial design, recruitment, site selection and other areas.

Genome Project 60

Genome Project Genome Genomics Medicine 60

Scienmag

MARCH 16, 2022

Bottom Line: Genomic sequencing of tumors from pediatric cancer patients experiencing a relapse enabled 107 patients to receive an appropriate matched therapy that is not the standard of care, according to data from the international clinical trial MAPPYACTS.

Genome 64

Genome Genomics Clinical Trials Clinical Trials 64

BioTech 365

OCTOBER 14, 2020

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Large genomics study points the way to future cancer clinical trials.Large genomics study points the way to future cancer clinical trials aliu Wed, 10/14/2020 – 04:56 from … Continue reading →

Genome 40

Genome Genomics Clinical Trials Clinical Trials 40

Drug Discovery World

MAY 17, 2024

Deepika Khedekar , Associate Centralized Clinical Trial Lead at IQVIA Inc, looks at the challenges of utilising artificial intelligence (AI) in oncology clinical research. MIT research 4 tells us a hard truth: about 95% of these trials fall short, leaving behind a trail of broken hopes for cancer patients each year.

Trials 52

Trials Clinical Trials Clinical Trials Protein 52

Scienmag

OCTOBER 13, 2020

NCI-MATCH precision medicine trial makes major contributions to the use of tumor gene testing to select treatment for patients; new data has broad relevance in medicine and provides a roadmap for future precision medicine trials Credit: ECOG-ACRIN Cancer Research Group Five years ago, the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and National Cancer (..)

Clinical Trials 88

Clinical Trials Clinical Trials Trials Genome 88

Medical Xpress

DECEMBER 6, 2022

Among premenopausal women with hormone receptor (HR)-positive, early-stage breast cancer enrolled in the SOFT trial, those with a high score on a genomic assay called Breast Cancer Index (BCI) had increased risk of distant recurrence, and those with low BCI benefited more from the addition of ovarian suppression therapy to endocrine therapy after 12 (..)

HR 63

HR Genome Genomics Hormones 63

Drug Discovery World

JANUARY 26, 2024

Delegates will hear how the integration of AI with cutting-edge technologies like patient-on-a-chip, real-time nano-sensing and stem cell genomic diversity is addressing the critical challenge of predicting drug behaviour in humans. See the full programme and register now to show your interest in attending this event.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Genome 52

Drug Discovery World

NOVEMBER 8, 2023

Deepika Khedekar , Associate Centralized Clinical Lead at IQVIA, explains how artificial intelligence could make clinical trials more accurate, accessible and standardised. Tapping into the capabilities of AI One reason AI may accelerate clinical trials is its ability to rapidly process and analyse vast amounts of data.

Clinical Trials 72

Clinical Trials Clinical Trials Trials Drugs 72

Pharmaceutical Technology

JUNE 20, 2023

The Department of Health Abu Dhabi (DoH) has signed a memorandum of understanding with integrated healthcare company M42 and AbbVie Biopharmaceuticals to advance personalised medicine and genomics in the city. M42 was created through the combination of Mubadala Health and G42 Healthcare.

Medicine 130

Medicine Genome Genomics Clinical Trials 130

Pharmaceutical Technology

SEPTEMBER 22, 2022

You have just received the results from your whole genome sequencing test, offered through your public health provider, and discovered that you have a 75% chance of developing a rare form of cancer. Alternatively, there are vaccines ready to enter decentralised third-phase clinical trials, so you can enrol quickly. It is the year 2030.

Genome 342

Genome Genomics Clinical Trials Clinical Trials 342

pharmaphorum

FEBRUARY 8, 2022

The rise in the use of decentralised clinical trial (DCTs) designs forced by COVID-19 looks set to outlast the pandemic, and digital health company Seqster has formed another partnership to tap into the shift from traditional site-based studies. The post UBC, Seqster join forces on patient-centric, remote trials appeared first on.

Trials 85

Trials Clinical Trials Clinical Trials Genome 85

Scienmag

MAY 19, 2021

Proprietary bioinformatics, paired with comprehensive clinical curation results in reporting that defines clinically actionable, FDA-approved, and clinical trial drug options for the management of the patient’s cancer.

Genome 41

Genome Genomics Bioinformatics FDA Approval 41

pharmaphorum

JANUARY 6, 2023

The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. The post UK partners with BioNTech on clinical trials of mRNA cancer therapies appeared first on.

Clinical Trials 111

Clinical Trials Clinical Trials Trials Vaccination 111

AuroBlog - Aurous Healthcare Clinical Trials blog

OCTOBER 3, 2023

Also companies like the healthtech startup HaystackAnalytics are engaged in developing India’s first Universal Infectious Disease (UID) genomic test, which highlights the need to put in place preventive health strategies. On the occasion of the […]

Production 155

Production Genome Genomics Development 155

pharmaphorum

MARCH 2, 2021

With COVID-19 forcing a shift towards decentralised trials, two digital health firms – Medable and Seqster – have teamed up to offer ways to also incorporate real-world data into remote study designs. . Patients want clinical trials to fit into their real-world experience, not the other way around,” according to Longmire.

Trials 98

Trials Clinical Trials Clinical Trials Life Science 98

AuroBlog - Aurous Healthcare Clinical Trials blog

NOVEMBER 1, 2022

As drug companies have embarked on an initiative to launch affordable medicines for rare diseases in India, experts have called for using pharmacogenetics to develop treatments and whole genome sequencing to identify etiologies.

Development 174

Development Genome Genomics Medicine 174

XTalks

JANUARY 17, 2024

To gain insights into how clinical trials for lupus can be enhanced with RWD sources, we spoke with Frederico Calado, VP of Global Real-World Solutions at Alira Health , and Dr. Kaleb Michaud, Professor, Division of Rheumatology, University of Nebraska Medical Center. Kaleb Michaud: In developing lupus solutions, RWD plays a crucial role.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Life Science 52

Worldwide Clinical Trials

FEBRUARY 6, 2023

When using genetic screening to identify clinical trial volunteers, a sponsor’s obligations for further testing and disclosure of results to patients and families are unclear, especially when the results have no impact on medical management. Guidance in this area is much needed. Read the full article!

Genetics 130

Genetics Clinical Trials Clinical Trials Genotype 130

Drug Discovery World

FEBRUARY 6, 2024

Her current work focuses on advancing the fields of genome sequencing and analysis, with an emphasis on identifying complex structural variation. She speaks to Megan Thomas on how genomics can advance drug discovery and development. MT: Where is technology being implemented to progress the drug discovery process?

Genome 59

Genome Genomics Genetics In-Vitro 59

pharmaphorum

OCTOBER 20, 2021

A software platform developed by Altoida that uses augmented reality and artificial intelligence to diagnose neurological diseases in their earliest stages is being tested in a five-year trial involving thousands of patients.

Trials 78

Trials Genome Genomics Bioinformatics 78

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

AuroBlog - Aurous Healthcare Clinical Trials blog

JUNE 11, 2023

The drug regulator, in a drug alert issued, said that a batch of Typbar, manufactured by Bharat Biotech International Ltd in Genome Valley in Hyderabad, Telangana, failed […]

Vaccination 126

Vaccination Vaccine Genome Genomics 126

Cloudbyz

APRIL 4, 2023

Clinical trials are crucial in bringing new treatments and therapies to patients. However, traditional clinical trial processes are often time-consuming, costly, and inefficient. DCTPs are designed to be user-friendly and accessible to anyone involved in the clinical trials process, including researchers, patients, and regulators.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Genome 52

The Pharma Data

JANUARY 26, 2021

offered its genomics expertise to identify emerging variants of the SARS-CoV-2 virus to countries that lack the resources to make such identifications. has carried out more than half of all SARS-CoV-2 genome sequences submitted to the global database. On Tuesday, the U.K. The offer came as part of the U.K.’s South Africa and Brazil.

Genome 52

Genome Genomics Vaccination Vaccine 52